| HOME >> BIOLOGY >> TECHNOLOGY |
FOSRENOL - Hyperphosphatemia
FOSRENOL has been launched in 25 countries and global sales totalled $36.2 million for the three months to March 31, 2008 (2007: $22.8 million). Outside the US, FOSRENOL has now been launched in Germany, France, UK, Italy and Spain (in January 2008) and a number of other countries. Sales of FOSRENOL outside the US for the three months ended March 31, 2008 were $15.6 million (2007: $6.5 million).
US sales of FOSRENOL for the three months to March 31, 2008 were up 26% to $20.6 million compared to the same period in 2007 (2007: $16.3 million). FOSRENOL's average market share of the US phosphate binder market decreased to 8.2% for the three months to March 31, 2008 (2007: 8.7%). Product sales increased despite the decline in US average market share due to price increases in October 2007 and February 2008.
DYNEPO - Anaemia associated with Chronic Kidney Disease ("CKD")
DYNEPO was launched in the UK, Germany, France, Italy and the Republic of Ireland in 2007. Product sales for the three months to March 31, 2008 were $6.7 million (2007: $nil).
XAGRID - Thrombocythemia
Sales for the three months to March 31, 2008 were $18.7 million, an increase of 29% compared to the same period in 2007 (2007: $14.5 million). Expressed in transaction currencies (XAGRID is primarily sold in Euros and Pounds Sterling), sales increased by 18% due to growth in many of Shire's existing markets, with exchange rate movements against the US dollar accounting for the remaining 11% increase.
Human Genetic Therapies
ELAPRASE - Hunter syndrome
Sales for the three months to March 31, 2008 were $71.5 million, an
increase of 169% compared to the same period in 2007 (2007: $26.6 million).
Sales growth continues to be driven by increased revenues in the US and EU
markets togethe
'/>"/>
| SOURCE Shire plc Copyright©2008 PR Newswire. All rights reserved |